- Report of Foreign Issuer (6-K)
February 16 2010 - 3:41PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of February 2010
001-33444
(Commission
File Number)
Eurand
N.V.
(Exact
Name of Registrant as Specified in Its Charter)
Not
Applicable
(Translation
of registrant’s name into English)
Olympic
Plaza
Fred.
Roeskestraat 123
1076
EE Amsterdam, The Netherlands
(Address
of principal corporate office)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F: Form 20-F
þ
Form 40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
o
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934: Yes
o
No
þ
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
INFORMATION
CONTAINED IN THIS FORM 6-K REPORT
Included
in this Report on Form 6-K as Exhibit 1 is a press release issued on February
16, 2010 by Eurand N.V., announcing the grant of U.S. Patent No. 7,658,918,
entitled “STABLE DIGESTIVE ENZYME COMPOSITIONS”, by the United States Patent and
Trademark Office.
The
information in this Report on Form 6-K shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or
otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.
Financial
Statements and Exhibits
Exhibit
# Description
1
|
Press
release titled
“Eurand
Issued U.S. Patent for ZENPEP
®
(pancrelipase)
Delayed-Release Capsules,”
issued on February 16,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: February
16, 2010
|
EURAND
N.V.
|
|
By:
|
/s/Manya S. Deehr
|
|
|
Manya
S. Deehr
|
|
|
Chief
Legal Officer & Secretary
|
EXHIBIT
INDEX
1
|
Press
release titled
“Eurand
Issued U.S. Patent for ZENPEP
®
(pancrelipase)
Delayed-Release Capsules,”
issued on February 16,
2010.
|
Eurand N.V. (MM) (NASDAQ:EURX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Eurand N.V. (MM) (NASDAQ:EURX)
Historical Stock Chart
From Aug 2023 to Aug 2024